<DOC>
	<DOCNO>NCT03082677</DOCNO>
	<brief_summary>This single arm open label phase 2 study evaluate potential effect ixazomib prevention recurrent late acute graft-versus-host disease ( GVHD ) chronic GVHD 1-year following reduce intensity ( RI ) non-myeloablative ( NMA ) allogeneic hematopoietic stem cell transplantation ( HSCT ) treatment hematologic malignancy .</brief_summary>
	<brief_title>Study Ixazomib Prevent Recurrent Late Acute Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Patients 18 year old . Diagnosis : myeloid lymphoid hematologic malignancy treat RI NMA condition HSCT receive calcineurin inhibitor base drug ( example : tacrolimus cyclosporin ) methotrexate part initial GVHD prophylaxis . Patients receive sirolimus part GVHD prophylaxis eligible . Recipients 87/8 HLAmatched donor . PostHSCT period within day +100 day +150 . Female patient : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing informed consent form 90 day last dose study drug , OR Agree practice true abstinence line prefer usual lifestyle subject ( periodic abstinence withdrawal acceptable method contraception ) . Male patient , even surgically sterilize ( i.e . Status postvasectomy ) must agree one following : Agree practice effective barrier contraception entire study treatment period 90 day last dose study drug , OR Agree practice true abstinence line prefer usual lifestyle subject ( periodic abstinence withdrawal acceptable method contraception ) . Organ Function Performance Status Criteria : Karnofsky score ≥ 70 % Absolute neutrophil count ( ANC ) ≥ 1000/mm3 platelet count ≥ 75,000/mm3 . Platelet transfusion help patient meet eligibility criterion allow within 3 day study enrollment . Calculated creatinine clearance ≥ 30 mL/min ( base Cockcroft Gault method ) Total bilirubin ≤ 1.5 x upper limit normal range ( ULN ) . AST/ALT ≤ 3 x ULN ( unless benign congenital hyperbilirubinemia ) . Disease : evidence progressive disease time study enrollment . Prior Therapy : one prior allogeneic stem cell transplantation ( prior autologous transplant acceptable ) . Active acute chronic GVHD . Active uncontrolled infection . Pregnant breast feeding . Major surgery within 14 day enrollment . Evidence current uncontrolled cardiovascular condition , include uncontrolled hypertension , uncontrolled cardiac arrhythmia , symptomatic congestive heart failure , unstable angina , myocardial infarction within past 6 month . Systemic treatment , within 14 day first dose ixazomib , strong inhibitor CYP1A2 ( fluvoxamine , enoxacin , ciprofloxacin ) , strong inhibitor CYP3A ( clarithromycin , telithromycin , itraconazole , voriconazole , ketoconazole , nefazodone , posaconazole ) strong CYP3A inducer ( rifampin , rifapentine , rifabutin , carbamazepine , phenytoin , phenobarbital ) , use Ginkgo biloba St. John 's wort . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Patient guardian unable give inform consent unable comply treatment protocol include appropriate supportive care , followup research test . Patients know allergy boron boroncontaining product , excipients various formulation agent . Known GI disease GI procedure could interfere oral absorption tolerance ixazomib include difficulty swallowing . Diagnosed treat another malignancy within 2 year study enrollment previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection . Patient ≥ Grade 3 peripheral neuropathy , Grade 2 pain clinical examination screen period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ixazomib</keyword>
	<keyword>Graft-versus-Host Disease</keyword>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>16-076</keyword>
</DOC>